Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This retrospective study will evaluate characteristics, vaccine utilization and outcomes among subjects with immunocompromising conditions that received COVID-19 vaccination.
The objective of this US-based retrospective cohort study is to evaluate characteristics, vaccine utilization and outcomes among subjects with immunocompromising conditions that received COVID-19 vaccination.
Subjects will be aged 12 years and older and will have no evidence of prior SARS-CoV-2 infection.
The primary analysis will be conducted on subjects vaccinated with BNT162b2.
A variety of subgroup analyses and sensitivity analyses are planned.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Immunocompromised | Vaccinated Subject with 1 or >1 immunocompromising conditions. |
| |
| Non-Immunocompromised | Vaccinated subjects without evidence of immunocompromising condition. |
| |
| Total Population (immunocompromised and non) | Vaccinated Subjects with or without 1 or >1 immunocompromising conditions. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| BNT162b2 (Tozinameran) | Biological | Covid-19 Vaccine |
|
| Measure | Description | Time Frame |
|---|---|---|
| Incidence Rate of Breakthrough Cases of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection | The incidence rate of breakthrough cases of SARS-CoV-2 infection was calculated as the number of participants who experienced the event divided by the observed time at risk and reported as incidence rate per 100 person-years. Rate of breakthrough SARS-CoV-2 infection among fully vaccinated participants was reported in this outcome measure. | From 14 days after Dose 2 of BNT162b2 vaccine up to COVID-19 vaccine breakthrough infection case or end of continuous enrollment, whichever occurred first (retrospective data was retrieved and observed during 4 months approximately) |
| Time to SARS-CoV-2 Breakthrough Infection | Time to SARS-CoV-2 breakthrough infection was calculated as the number of days from Dose 2 of vaccination till first occurrence of a breakthrough SARS-CoV-2 infection. | From 14 days after Dose 2 of BNT162b2 vaccine up to COVID-19 vaccine breakthrough infection case or end of continuous enrollment, whichever occurred first (retrospective data was retrieved and observed during 4 months approximately) |
| Measure | Description | Time Frame |
|---|---|---|
| Number of Participants With Emergency Department Visits After SARS-CoV-2 Infection | In this outcome measure, number of participants with emergency department visits who were fully vaccination and had SARS-CoV-2 breakthrough infection were analyzed. Emergency department visits included an outpatient claim that occurs after the breakthrough COVID-19 diagnosis date or at the same time or episode of care. |
Not provided
Inclusion Criteria:
Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study:
Subjects with an IC condition will be identified via an algorithm developed for use in administrative claims database studies.
Exclusion criteria: subjects not meeting the criteria above will be excluded.
Not provided
Not provided
Not provided
The main study population consists of subjects >12 that received Covid-19 vaccination, had no evidence of prior infection, had continuous enrollment and evidence of immunocompromising conditions during the baseline pre vaccination period.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Pfizer CT.gov Call Center | Pfizer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Pfizer Inc. | New York | New York | 10021 | United States |
Not provided
| Label | URL |
|---|---|
| To obtain contact information for a study center near you, click here. | View source |
Not provided
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical\_trials/trial\_data\_and\_results/data\_requests.
Not provided
Not provided
Not provided
Not provided
Not provided
Data of participants aged 12 years or more with at least 1 BNT162b2 vaccine claim between 10 Dec 2020 to 08 Jul 2021 examined for COVID-19 breakthrough infections (vaccination greater than equal to [>=] 14 days after 2nd dose) in real-world practice, were retrieved from US HealthVerity database. Available data were extracted and evaluated during approximately 4 months of this retrospective observational study.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | BNT162b2 (Tozinameran): IC Cohort | Participants with IC condition who had at least 1 BNT162b2 vaccine claim between 10 December 2020 to 08 July 2021 were retrospectively observed in this cohort. Participants were considered immunocompromised if they had >=1 hospitalization or >=2 outpatient visits on separate dates on a healthcare claim indicated 1 or more IC condition or if they had usage of specific immunosuppressive (IS) medications during the 12-month baseline period (prior to index period). Index date was defined as the date of receipt of the 1st BNT162b2 dose. |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Aug 25, 2021 |
Not provided
Not provided
Not provided
Not provided
|
| From 14 days after Dose 2 of BNT162b2 vaccine up to COVID-19 vaccine breakthrough infection case or end of continuous enrollment, whichever occurred first (retrospective data was retrieved and observed during 4 months approximately) |
| Number of Participants With Outpatient Hospital Visits After SARS-CoV-2 Infection | In this outcome measure, number of participants with outpatient hospital visits who were fully vaccination and had SARS-CoV-2 breakthrough infection were analyzed. Outpatient hospital visits included an outpatient claim that occurs after the breakthrough COVID-19 diagnosis date or at the same time or episode of care other than emergency department visits. | From 14 days after Dose 2 of BNT162b2 vaccine up to COVID-19 vaccine breakthrough infection case or end of continuous enrollment, whichever occurred first (retrospective data was retrieved and observed during 4 months approximately) |
| Number of Participants With Other Outpatient Visits After SARS-CoV-2 Infection | In this outcome measure, number of participants with other outpatient visits (excluding emergency department visits and outpatient hospital visits) who were fully vaccination and had SARS-CoV-2 breakthrough infection were analyzed. | From 14 days after Dose 2 of BNT162b2 vaccine up to COVID-19 vaccine breakthrough infection case or end of continuous enrollment, whichever occurred first (retrospective data was retrieved and observed during 4 months approximately) |
| Number of Participants Hospitalized After SARS-CoV-2 Infection | In this outcome measure, number of participants hospitalized who were fully vaccination and had SARS-CoV-2 breakthrough infection were analyzed. | From 14 days after Dose 2 of BNT162b2 vaccine up to COVID-19 vaccine breakthrough infection case or end of continuous enrollment, whichever occurred first (retrospective data was retrieved and observed during 4 months approximately) |
| Number of Participants Admitted to Intensive Care Unit (ICU) During Hospitalization After SARS-CoV-2 Infection | In this outcome measure, number of participants admitted to ICU with or without Invasive Mechanical Ventilation (IMV) during hospitalization who were fully vaccination and had SARS-CoV-2 breakthrough infection were analyzed. | From 14 days after Dose 2 of BNT162b2 vaccine up to COVID-19 vaccine breakthrough infection case or end of continuous enrollment, whichever occurred first (retrospective data was retrieved and observed during 4 months approximately) |
| Number of Participants Who Received Invasive Mechanical Ventilation (IMV) During Hospitalization After SARS-CoV-2 Infection | In this outcome measure, number of participants who received IMV with or without ICU admission during hospitalization who were fully vaccination and had SARS-CoV-2 breakthrough infection were analyzed. | From 14 days after Dose 2 of BNT162b2 vaccine up to COVID-19 vaccine breakthrough infection case or end of continuous enrollment, whichever occurred first (retrospective data was retrieved and observed during 4 months approximately) |
| Number of Participants Died During Hospitalization After SARS-CoV-2 Infection | In this outcome measure, number of participants who died during hospitalization who were fully vaccination and had SARS-CoV-2 breakthrough infection were analyzed. | From 14 days after Dose 2 of BNT162b2 vaccine up to COVID-19 vaccine breakthrough infection case or end of continuous enrollment, whichever occurred first (retrospective data was retrieved and observed during 4 months approximately) |
| Total Duration of Stay in Hospital After SARS-CoV-2 Infection | Total duration of stay was total time spend by the participant for different types of hospitalization treatments, applicable for first hospitalization and/or readmissions. | From Dose 2 of COVID-19 vaccination till the end of study (retrospective data was retrieved and observed during 4 months of this study) |
| Total Expenditure on Healthcare Resource Utilization (HCRU) After SARS-CoV-2 Infection | Total expenditure on HCRU was defined as total non-zero costs associated with any of the previously listed outpatient and inpatient encounters. | From Dose 2 of COVID-19 vaccination till the end of study (retrospective data was retrieved and observed during 4 months of this study) |
| FG001 | BNT162b2 (Tozinameran): Non-IC Cohort | Participants who had at least 1 BNT162b2 vaccine claim between 10 December 2020 to 08 July 2021 and without evidence of immunocompromising condition were included in this reporting arm. |
| Fully Vaccinated |
|
| COMPLETED |
|
| NOT COMPLETED |
|
Analysis population included all participants at least 12 years of age with at least one vaccine claim between 10 Dec 2020 to 08 Jul 2021 from the HealthVerity health care database, had 12 months of continuous medical enrollment prior to the receipt of their first vaccine with no evidence of a SARS-CoV-2 infection in the year prior to being vaccinated.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | BNT162b2 (Tozinameran): IC Cohort | Participants with IC condition who had at least 1 BNT162b2 vaccine claim between 10 December 2020 to 08 July 2021 were retrospectively observed in this cohort. Participants were considered immunocompromised if they had >=1 hospitalization or >=2 outpatient visits on separate dates on a healthcare claim indicated 1 or more IC condition or if they had usage of specific immunosuppressive (IS) medications during the 12-month baseline period (prior to index period). Index date was defined as the date of receipt of the 1st BNT162b2 dose. |
| BG001 | BNT162b2 (Tozinameran): Non-IC Cohort | Participants who had at least 1 BNT162b2 vaccine claim between 10 December 2020 to 08 July 2021 and without evidence of immunocompromising condition were included in this reporting arm. |
| BG002 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean | Standard Deviation | Years |
| |||||||||||||||
| Sex/Gender, Customized | Count of Participants | Participants |
| ||||||||||||||||
| Race and Ethnicity Not Collected | Race and Ethnicity were not collected from any participant. | Count of Participants | Participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Incidence Rate of Breakthrough Cases of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection | The incidence rate of breakthrough cases of SARS-CoV-2 infection was calculated as the number of participants who experienced the event divided by the observed time at risk and reported as incidence rate per 100 person-years. Rate of breakthrough SARS-CoV-2 infection among fully vaccinated participants was reported in this outcome measure. | Analysis population included fully vaccinated participants against COVID-19 in dataset during 10-Dec-2020 through 08-Jul-2021, at least 12 years old on index date, had continuous medical enrolment 12-month period prior to index date, with no prior COVID-19 diagnosis during baseline. Fully vaccinated was defined as >=14 days of follow-up after Dose 2 of BNT162b2 vaccine. Here, N=participant who had at least 1 incidence of SARS-CoV-2 breakthrough infection were evaluable for this outcome measure. | Posted | Number | 95% Confidence Interval | Events per 100 person-years | From 14 days after Dose 2 of BNT162b2 vaccine up to COVID-19 vaccine breakthrough infection case or end of continuous enrollment, whichever occurred first (retrospective data was retrieved and observed during 4 months approximately) |
|
|
| ||||||||||||||||||||||||||||
| Primary | Time to SARS-CoV-2 Breakthrough Infection | Time to SARS-CoV-2 breakthrough infection was calculated as the number of days from Dose 2 of vaccination till first occurrence of a breakthrough SARS-CoV-2 infection. | Analysis population included fully vaccinated participants against COVID-19 in dataset during 10-Dec-2020 through 08-Jul-2021, at least 12 years old on index date, had continuous medical enrolment 12-month period prior to index date, with no prior COVID-19 diagnosis during baseline. Fully vaccinated was defined as >=14 days of follow-up after Dose 2 of BNT162b2 vaccine. Here, N=participant who had at least 1 incidence of SARS-CoV-2 breakthrough infection were evaluable for this outcome measure. | Posted | Median | Inter-Quartile Range | Days | From 14 days after Dose 2 of BNT162b2 vaccine up to COVID-19 vaccine breakthrough infection case or end of continuous enrollment, whichever occurred first (retrospective data was retrieved and observed during 4 months approximately) |
| ||||||||||||||||||||||||||||||
| Secondary | Number of Participants With Emergency Department Visits After SARS-CoV-2 Infection | In this outcome measure, number of participants with emergency department visits who were fully vaccination and had SARS-CoV-2 breakthrough infection were analyzed. Emergency department visits included an outpatient claim that occurs after the breakthrough COVID-19 diagnosis date or at the same time or episode of care. | Analysis population included fully vaccinated participants against COVID-19 in dataset during 10-Dec-2020 through 08-Jul-2021, at least 12 years old on index date, had continuous medical enrolment 12-month period prior to index date, with no prior COVID-19 diagnosis during baseline. Fully vaccinated was defined as >=14 days of follow-up after Dose 2 of BNT162b2 vaccine. Here, N=participant who had at least 1 incidence of SARS-CoV-2 breakthrough infection were evaluable for this outcome measure. | Posted | Count of Participants | Participants | From 14 days after Dose 2 of BNT162b2 vaccine up to COVID-19 vaccine breakthrough infection case or end of continuous enrollment, whichever occurred first (retrospective data was retrieved and observed during 4 months approximately) |
| |||||||||||||||||||||||||||||||
| Secondary | Number of Participants With Outpatient Hospital Visits After SARS-CoV-2 Infection | In this outcome measure, number of participants with outpatient hospital visits who were fully vaccination and had SARS-CoV-2 breakthrough infection were analyzed. Outpatient hospital visits included an outpatient claim that occurs after the breakthrough COVID-19 diagnosis date or at the same time or episode of care other than emergency department visits. | Analysis population included fully vaccinated participants against COVID-19 in dataset during 10-Dec-2020 through 08-Jul-2021, at least 12 years old on index date, had continuous medical enrolment 12-month period prior to index date, with no prior COVID-19 diagnosis during baseline. Fully vaccinated was defined as >=14 days of follow-up after Dose 2 of BNT162b2 vaccine. Here, N=participant who had at least 1 incidence of SARS-CoV-2 breakthrough infection were evaluable for this outcome measure. | Posted | Count of Participants | Participants | From 14 days after Dose 2 of BNT162b2 vaccine up to COVID-19 vaccine breakthrough infection case or end of continuous enrollment, whichever occurred first (retrospective data was retrieved and observed during 4 months approximately) |
| |||||||||||||||||||||||||||||||
| Secondary | Number of Participants With Other Outpatient Visits After SARS-CoV-2 Infection | In this outcome measure, number of participants with other outpatient visits (excluding emergency department visits and outpatient hospital visits) who were fully vaccination and had SARS-CoV-2 breakthrough infection were analyzed. | Analysis population included fully vaccinated participants against COVID-19 in dataset during 10-Dec-2020 through 08-Jul-2021, at least 12 years old on index date, had continuous medical enrolment 12-month period prior to index date, with no prior COVID-19 diagnosis during baseline. Fully vaccinated was defined as >=14 days of follow-up after Dose 2 of BNT162b2 vaccine. Here, N=participant who had at least 1 incidence of SARS-CoV-2 breakthrough infection were evaluable for this outcome measure. | Posted | Count of Participants | Participants | From 14 days after Dose 2 of BNT162b2 vaccine up to COVID-19 vaccine breakthrough infection case or end of continuous enrollment, whichever occurred first (retrospective data was retrieved and observed during 4 months approximately) |
| |||||||||||||||||||||||||||||||
| Secondary | Number of Participants Hospitalized After SARS-CoV-2 Infection | In this outcome measure, number of participants hospitalized who were fully vaccination and had SARS-CoV-2 breakthrough infection were analyzed. | Analysis population included fully vaccinated participants against COVID-19 in dataset during 10-Dec-2020 through 08-Jul-2021, at least 12 years old on index date, had continuous medical enrolment 12-month period prior to index date, with no prior COVID-19 diagnosis during baseline. Fully vaccinated was defined as >=14 days of follow-up after Dose 2 of BNT162b2 vaccine. Here, N=participant who had at least 1 incidence of SARS-CoV-2 breakthrough infection were evaluable for this outcome measure. | Posted | Count of Participants | Participants | From 14 days after Dose 2 of BNT162b2 vaccine up to COVID-19 vaccine breakthrough infection case or end of continuous enrollment, whichever occurred first (retrospective data was retrieved and observed during 4 months approximately) |
| |||||||||||||||||||||||||||||||
| Secondary | Number of Participants Admitted to Intensive Care Unit (ICU) During Hospitalization After SARS-CoV-2 Infection | In this outcome measure, number of participants admitted to ICU with or without Invasive Mechanical Ventilation (IMV) during hospitalization who were fully vaccination and had SARS-CoV-2 breakthrough infection were analyzed. | Analysis population included fully vaccinated participants against COVID-19 in dataset during 10-Dec-2020 through 08-Jul-2021, at least 12 years old on index date, had continuous medical enrolment 12-month period prior to index date, with no prior COVID-19 diagnosis during baseline. Fully vaccinated was defined as >=14 days of follow-up after Dose 2 of BNT162b2 vaccine. Here, N=participant who had at least 1 incidence of SARS-CoV-2 breakthrough infection were evaluable for this outcome measure. | Posted | Count of Participants | Participants | From 14 days after Dose 2 of BNT162b2 vaccine up to COVID-19 vaccine breakthrough infection case or end of continuous enrollment, whichever occurred first (retrospective data was retrieved and observed during 4 months approximately) |
| |||||||||||||||||||||||||||||||
| Secondary | Number of Participants Who Received Invasive Mechanical Ventilation (IMV) During Hospitalization After SARS-CoV-2 Infection | In this outcome measure, number of participants who received IMV with or without ICU admission during hospitalization who were fully vaccination and had SARS-CoV-2 breakthrough infection were analyzed. | Analysis population included fully vaccinated participants against COVID-19 in dataset during 10-Dec-2020 through 08-Jul-2021, at least 12 years old on index date, had continuous medical enrolment 12-month period prior to index date, with no prior COVID-19 diagnosis during baseline. Fully vaccinated was defined as >=14 days of follow-up after Dose 2 of BNT162b2 vaccine. Here, N=participant who had at least 1 incidence of SARS-CoV-2 breakthrough infection were evaluable for this outcome measure. | Posted | Count of Participants | Participants | From 14 days after Dose 2 of BNT162b2 vaccine up to COVID-19 vaccine breakthrough infection case or end of continuous enrollment, whichever occurred first (retrospective data was retrieved and observed during 4 months approximately) |
| |||||||||||||||||||||||||||||||
| Secondary | Number of Participants Died During Hospitalization After SARS-CoV-2 Infection | In this outcome measure, number of participants who died during hospitalization who were fully vaccination and had SARS-CoV-2 breakthrough infection were analyzed. | Analysis population included fully vaccinated participants against COVID-19 in dataset during 10-Dec-2020 through 08-Jul-2021, at least 12 years old on index date, had continuous medical enrolment 12-month period prior to index date, with no prior COVID-19 diagnosis during baseline. Fully vaccinated was defined as >=14 days of follow-up after Dose 2 of BNT162b2 vaccine. Here, N=participant who had at least 1 incidence of SARS-CoV-2 breakthrough infection were evaluable for this outcome measure. | Posted | Count of Participants | Participants | From 14 days after Dose 2 of BNT162b2 vaccine up to COVID-19 vaccine breakthrough infection case or end of continuous enrollment, whichever occurred first (retrospective data was retrieved and observed during 4 months approximately) |
| |||||||||||||||||||||||||||||||
| Secondary | Total Duration of Stay in Hospital After SARS-CoV-2 Infection | Total duration of stay was total time spend by the participant for different types of hospitalization treatments, applicable for first hospitalization and/or readmissions. | Data was not collected and analyzed for this outcome measure as per Sponsor discretion. | Posted | From Dose 2 of COVID-19 vaccination till the end of study (retrospective data was retrieved and observed during 4 months of this study) |
| |||||||||||||||||||||||||||||||||
| Secondary | Total Expenditure on Healthcare Resource Utilization (HCRU) After SARS-CoV-2 Infection | Total expenditure on HCRU was defined as total non-zero costs associated with any of the previously listed outpatient and inpatient encounters. | Data was not collected and analyzed for this outcome measure as per Sponsor discretion. | Posted | From Dose 2 of COVID-19 vaccination till the end of study (retrospective data was retrieved and observed during 4 months of this study) |
|
Adverse events were not planned to be collected hence time frame was not applicable
In this study individual participant data was not retrieved or validated, and it was not possible to link a particular product and medical event for any individual. Thus, the minimum criteria for reporting an adverse event (AE) cannot be met. Hence, AEs were not collected and reported in this study.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | BNT162b2 (Tozinameran): IC Cohort | Participants with IC condition who had at least 1 BNT162b2 vaccine claim between 10 December 2020 to 08 July 2021 were retrospectively observed in this cohort. Participants were considered immunocompromised if they had >=1 hospitalization or >=2 outpatient visits on separate dates on a healthcare claim indicated 1 or more IC condition or if they had usage of specific immunosuppressive (IS) medications during the 12-month baseline period (prior to index period). Index date was defined as the date of receipt of the 1st BNT162b2 dose. | 0 | 0 | 0 | 0 | 0 | 0 |
| EG001 | BNT162b2 (Tozinameran): Non-IC Cohort | Participants who had at least 1 BNT162b2 vaccine claim between 10 December 2020 to 08 July 2021 and without evidence of immunocompromising condition were included in this reporting arm. | 0 | 0 | 0 | 0 | 0 | 0 |
Not provided
Not provided
Data for outcome measures- Total duration of stay in hospital after SARS-COV-2 infection and total expenditure on healthcare resource utilization (HCRU) after SARS-COV-2 infection was not collected and analyzed as per Sponsor discretion.
Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Pfizer ClinicalTrials.gov Call Center | Pfizer Inc. | 1-800-718-1021 | ClinicalTrials.gov_Inquiries@pfizer.com |
| Nov 22, 2022 |
| Prot_SAP_000.pdf |
| ID | Term |
|---|---|
| D000086382 | COVID-19 |
| D000093742 | Breakthrough Infections |
| ID | Term |
|---|---|
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
| D014777 | Virus Diseases |
| D018352 | Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| D000090982 | BNT162 Vaccine |
| ID | Term |
|---|---|
| D000087503 | mRNA Vaccines |
| D000087504 | Nucleic Acid-Based Vaccines |
| D014614 | Vaccines, Synthetic |
| D011994 | Recombinant Proteins |
| D011506 | Proteins |
| D000602 | Amino Acids, Peptides, and Proteins |
| D014612 | Vaccines |
| D001688 | Biological Products |
| D045424 | Complex Mixtures |
| D000086663 | COVID-19 Vaccines |
| D014765 | Viral Vaccines |
| D000941 | Antigens |
| D001685 | Biological Factors |
Not provided
Not provided
|
|
| BNT162b2 (Tozinameran): Non-IC Cohort |
Participants who had at least 1 BNT162b2 vaccine claim between 10 December 2020 to 08 July 2021 and without evidence of immunocompromising condition were included in this reporting arm. |
|
|
| OG001 | BNT162b2 (Tozinameran): Non-IC Cohort | Participants who had at least 1 BNT162b2 vaccine claim between 10 December 2020 to 08 July 2021 and without evidence of immunocompromising condition were included in this reporting arm. |
|
|
| OG001 | BNT162b2 (Tozinameran): Non-IC Cohort | Participants who had at least 1 BNT162b2 vaccine claim between 10 December 2020 to 08 July 2021 and without evidence of immunocompromising condition were included in this reporting arm. |
|
|
| OG001 | BNT162b2 (Tozinameran): Non-IC Cohort | Participants who had at least 1 BNT162b2 vaccine claim between 10 December 2020 to 08 July 2021 and without evidence of immunocompromising condition were included in this reporting arm. |
|
|
| BNT162b2 (Tozinameran): Non-IC Cohort |
Participants who had at least 1 BNT162b2 vaccine claim between 10 December 2020 to 08 July 2021 and without evidence of immunocompromising condition were included in this reporting arm. |
|
|
| OG001 | BNT162b2 (Tozinameran): Non-IC Cohort | Participants who had at least 1 BNT162b2 vaccine claim between 10 December 2020 to 08 July 2021 and without evidence of immunocompromising condition were included in this reporting arm. |
|
|
| OG001 | BNT162b2 (Tozinameran): Non-IC Cohort | Participants who had at least 1 BNT162b2 vaccine claim between 10 December 2020 to 08 July 2021 and without evidence of immunocompromising condition were included in this reporting arm. |
|
|
| OG001 |
| BNT162b2 (Tozinameran): Non-IC Cohort |
Participants who had at least 1 BNT162b2 vaccine claim between 10 December 2020 to 08 July 2021 and without evidence of immunocompromising condition were included in this reporting arm. |
|
|
| Units | Counts |
|---|---|
| Participants |
|
| Units | Counts |
|---|---|
| Participants |
|